Literature DB >> 22411289

Antiplatelet therapy: Does CYP2C19 genotype affect clinical outcome?

Jurriën M ten Berg, Vera H Deneer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22411289     DOI： 10.1038/nrcardio.2012.29

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  9 in total

1.  Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.

Authors:  Guillaume Paré; Shamir R Mehta; Salim Yusuf; Sonia S Anand; Stuart J Connolly; Jack Hirsh; Katy Simonsen; Deepak L Bhatt; Keith A A Fox; John W Eikelboom
Journal:  N Engl J Med       Date:  2010-08-29       Impact factor: 91.245

2.  Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

Authors:  Jessica L Mega; Tabassome Simon; Jean-Philippe Collet; Jeffrey L Anderson; Elliott M Antman; Kevin Bliden; Christopher P Cannon; Nicolas Danchin; Betti Giusti; Paul Gurbel; Benjamin D Horne; Jean-Sebastian Hulot; Adnan Kastrati; Gilles Montalescot; Franz-Josef Neumann; Lei Shen; Dirk Sibbing; P Gabriel Steg; Dietmar Trenk; Stephen D Wiviott; Marc S Sabatine
Journal:  JAMA       Date:  2010-10-27       Impact factor: 56.272

Review 3.  CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.

Authors:  Michael V Holmes; Pablo Perel; Tina Shah; Aroon D Hingorani; Juan P Casas
Journal:  JAMA       Date:  2011-12-28       Impact factor: 56.272

4.  Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.

Authors:  Jessica L Mega; Willibald Hochholzer; Andrew L Frelinger; Michael J Kluk; Dominick J Angiolillo; Dean J Kereiakes; Steven Isserman; William J Rogers; Christian T Ruff; Charles Contant; Michael J Pencina; Benjamin M Scirica; Janina A Longtine; Alan D Michelson; Marc S Sabatine
Journal:  JAMA       Date:  2011-11-16       Impact factor: 56.272

5.  Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy.

Authors:  D Sibbing; D Gebhard; W Koch; S Braun; J Stegherr; T Morath; N Von Beckerath; J Mehilli; A Schömig; T Schuster; A Kastrati
Journal:  J Thromb Haemost       Date:  2010-05-21       Impact factor: 5.824

6.  Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.

Authors:  Lars Wallentin; Stefan James; Robert F Storey; Martin Armstrong; Bryan J Barratt; Jay Horrow; Steen Husted; Hugo Katus; P Gabriel Steg; Svati H Shah; Richard C Becker
Journal:  Lancet       Date:  2010-10-16       Impact factor: 79.321

7.  Cytochrome p-450 polymorphisms and response to clopidogrel.

Authors:  Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Richard D Hockett; John T Brandt; Joseph R Walker; Elliott M Antman; William Macias; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

8.  Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.

Authors:  Miho Kazui; Yumi Nishiya; Tomoko Ishizuka; Katsunobu Hagihara; Nagy A Farid; Osamu Okazaki; Toshihiko Ikeda; Atsushi Kurihara
Journal:  Drug Metab Dispos       Date:  2010-01       Impact factor: 3.922

Review 9.  Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.

Authors:  Jaapjan D Snoep; Marcel M C Hovens; Jeroen C J Eikenboom; Johanna G van der Bom; J Wouter Jukema; Menno V Huisman
Journal:  Am Heart J       Date:  2007-08       Impact factor: 4.749
  9 in total
  2 in total

Review 1.  Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?

Authors:  Mohamed H A Shahin; Julie A Johnson
Journal:  Curr Opin Cardiol       Date:  2013-05       Impact factor: 2.161

2.  Electrochemical immunosensor development based on core-shell high-crystalline graphitic carbon nitride@carbon dots and Cd0.5Zn0.5S/d-Ti3C2Tx MXene composite for heart-type fatty acid-binding protein detection.

Authors:  Ceren Karaman; Onur Karaman; Necip Atar; Mehmet Lütfi Yola
Journal:  Mikrochim Acta       Date:  2021-05-07       Impact factor: 5.833
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.